🚀 VC round data is live in beta, check it out!
CHO Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for CHO Pharma and similar public comparables like DiaMedica, Bicycle Therapeutics, Cuorips, Surrozen and more.
CHO Pharma Overview
About CHO Pharma
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
Founded
2013
HQ
Employees
41
Website
Sectors
Financials (FY)
EV
$299M
CHO Pharma Financials
CHO Pharma reported last fiscal year revenue of $114K and negative EBITDA of ($6M).
In the same fiscal year, CHO Pharma generated $54K in gross profit, ($6M) in EBITDA losses, and had net loss of ($7M).
CHO Pharma P&L
In the most recent fiscal year, CHO Pharma reported revenue of $114K and EBITDA of ($6M).
CHO Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $114K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $54K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5186%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (6963%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (5928%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CHO Pharma Stock Performance
CHO Pharma has current market cap of $369M, and enterprise value of $299M.
Market Cap Evolution
CHO Pharma's stock price is $1.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $299M | $369M | 0.5% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCHO Pharma Valuation Multiples
CHO Pharma trades at 2624.1x EV/Revenue multiple, and (50.6x) EV/EBITDA.
CHO Pharma Financial Valuation Multiples
As of April 19, 2026, CHO Pharma has market cap of $369M and EV of $299M.
Equity research analysts estimate CHO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CHO Pharma has a P/E ratio of (54.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $369M | XXX | $369M | XXX | XXX | XXX |
| EV (current) | $299M | XXX | $299M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2624.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (50.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (37.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5493.7x | XXX | XXX | XXX |
| P/E | — | XXX | (54.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (42.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CHO Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CHO Pharma Margins & Growth Rates
CHO Pharma's revenue in the last fiscal year grew by —.
CHO Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
CHO Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (5186%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (33%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 266% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 626% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6119% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 7011% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CHO Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CHO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| DiaMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicycle Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cuorips | XXX | XXX | XXX | XXX | XXX | XXX |
| Surrozen | XXX | XXX | XXX | XXX | XXX | XXX |
| Akebia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CHO Pharma M&A Activity
CHO Pharma acquired XXX companies to date.
Last acquisition by CHO Pharma was on XXXXXXXX, XXXXX. CHO Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CHO Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCHO Pharma Investment Activity
CHO Pharma invested in XXX companies to date.
CHO Pharma made its latest investment on XXXXXXXX, XXXXX. CHO Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CHO Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CHO Pharma
| When was CHO Pharma founded? | CHO Pharma was founded in 2013. |
| Where is CHO Pharma headquartered? | CHO Pharma is headquartered in Taiwan. |
| How many employees does CHO Pharma have? | As of today, CHO Pharma has over 41 employees. |
| Is CHO Pharma publicly listed? | Yes, CHO Pharma is a public company listed on Taipei Exchange. |
| What is the stock symbol of CHO Pharma? | CHO Pharma trades under 6586 ticker. |
| When did CHO Pharma go public? | CHO Pharma went public in 2017. |
| Who are competitors of CHO Pharma? | CHO Pharma main competitors are DiaMedica, Bicycle Therapeutics, Cuorips, Surrozen. |
| What is the current market cap of CHO Pharma? | CHO Pharma's current market cap is $369M. |
| What is the current revenue of CHO Pharma? | CHO Pharma's last fiscal year revenue is $114K. |
| What is the current EV/Revenue multiple of CHO Pharma? | Current revenue multiple of CHO Pharma is 2624.1x. |
| Is CHO Pharma profitable? | No, CHO Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.